IPM Take
This is the kind of oncology result that changes the room. Pancreatic cancer has spent years as the disease where precision medicine promised more than it delivered. Daraxonrasib changes that conversation. But the political question starts immediately: if a RAS-targeted pill nearly doubled median overall survival in the trial in a lethal cancer, how quickly can systems identify eligible patients, approve the drug, pay for it, and make sure access is not limited to centres already wired into trial networks?
Executive Summary
At ASCO 2026, results from the phase III RASolute 302 trial showed that once-daily oral daraxonrasib, a multi-selective RAS(ON) inhibitor, significantly improved outcomes in previously treated metastatic pancreatic ductal adenocarcinoma. The trial enrolled 500 patients across North America, Europe and Asia. Median overall survival reached 13.2 months with daraxonrasib compared with around 6.6 to 6.7 months with chemotherapy. The results were also published in The New England Journal of Medicine. Daraxonrasib remains investigational, but the data support a strong regulatory and access case.
Why it matters
- Regulators: Will face pressure to review a therapy that could reset expectations in second-line metastatic pancreatic cancer.
- Payers / HTA bodies: Need to prepare for value assessment in a high-mortality cancer where survival gains are clinically meaningful but budget impact may be large.
- Hospitals / clinicians: Need clear pathways for eligibility assessment, referral, expanded access where available, and future treatment sequencing.
For years, pancreatic cancer has been the place where oncology innovation hit a wall. KRAS was known to drive most pancreatic ductal adenocarcinomas, but knowing the biology did not mean having a treatment that could change outcomes.
That is what makes RASolute 302 politically and clinically important. Daraxonrasib did not offer a marginal signal. It produced a survival result that immediately shifts the question from “can RAS be targeted?” to “how fast can health systems act when it is?”
The affected population is specific: patients with previously treated metastatic pancreatic ductal adenocarcinoma. But the signal is bigger than one line of therapy. A broadly active RAS(ON) inhibitor could reshape how clinicians think about pancreatic cancer, and possibly other RAS-driven tumours, if future trials confirm broader utility.
The implementation problem is already visible. If approved, daraxonrasib will need rapid integration into oncology pathways, including diagnostic testing, reimbursement, specialist referral and sequencing after first-line chemotherapy. Patients with metastatic pancreatic cancer do not have time for slow access machinery.
For IPM, this is a last-mile case in its purest form. The science has moved. Now the system has to prove it can move too.
